Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations
医学
内科学
肿瘤科
临床研究阶段
临床试验
作者
David S. Hong,Federico Cappuzzo,Byoung Chul Cho,Afshin Dowlati,Maen Hussein,Dong‐Wan Kim,Ivor Percent,James G. Christensen,Josée Morin,Diane Potvin,Demiana Faltaos,Vanessa Tassell,Hirak Der-Torossian,Richard C. Chao
出处
期刊:Lung Cancer [Elsevier] 日期:2024-02-01卷期号:: 107512-107512